[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646501":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":24,"armGroups":25,"interventions":20,"overallOfficials":32,"centralContacts":38,"locations":43,"responsibleParty":58,"collaborators":20,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":27,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":20,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":46,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Yale University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Collection and annotation of biospecimens","Facilitate and streamline the collection, banking, and clinical annotation of liquid biopsy biospecimens (peripheral blood collected in Streck Cell-Free DNA BCT® tubes or blood spots) - and, optionally, corresponding archival tumor specimens - for cancer research studies across Yale Cancer Center and the Smilow Cancer Hospital network.","Through study completion, up to 5 years",[14,17],{"measure":15,"description":16,"timeFrame":12},"Establish a repository","Establish a repository of clinically annotated liquid biopsy biospecimens (and optional archival tumor specimens) for current and future research.",{"measure":18,"description":19,"timeFrame":12},"Collection of blood for additional methods","Facilitate the collection of blood for additional methods of scientific analysis in parallel with cfNA analysis.",null,{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":22,"timePerspective":23,"maskingInfo":20},"COHORT","PROSPECTIVE","UNIFY will enroll Yale Cancer Center patients with histologically or radiologically suspected or confirmed solid tumor or hematologic malignancy of any type or stage, as well as individuals identified as high-risk for cancer.",[26,29],{"label":27,"type":20,"description":28,"interventionNames":20},"UNIFY","Patients enrolled in UNIFY only, with biological samples and limited clinical data collected as stipulated by this protocol",{"label":30,"type":20,"description":31,"interventionNames":20},"UNIFY plus","UNIFY plus a co-enrolled primary research study: Patients concurrently enrolled in a separate IRB-approved under UNIFY, limited clinical data will be collected for this cohort under the primary research study that requires blood sampling and optional or mandatory tumor tissue collection for research purposes.",[33,36],{"name":34,"affiliation":5,"role":35},"Mitchell Elliott, MD","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":5,"role":35},"Maryam Lustberg, MD, MPH",[39],{"name":34,"role":40,"phone":41,"phoneExt":20,"email":42},"CONTACT","475-375-7981","Mitchell.elliott@yale.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":20},"Smilow Cancer Hospital","RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-72.92816,41.30815,{"lat":56,"lon":55},{"type":59,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100646501","unified-network-for-integrated-fluid-collection-at-yale-100646501",false,"NCT07689864","Unified Network for Integrated Fluid Collection at Yale","Inclusion Criteria:\n\n* Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and\u002For significant family history of malignancy).\n* Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY.\n* If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).","ALL","18 Years",{"count":69,"type":70},2500,"ESTIMATED","OBSERVATIONAL","UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.",[74,75],"Molecular Residual Disease","Cancer",[77],"Liquid Biopsy","2026-08-24",{"date":80,"type":81},"2026-08-25","ACTUAL",{"date":80,"type":81},{"date":84,"type":70},"2031-08",{"name":5,"class":6},1]